The relatively recovered and intact T-cell immune system in these patients and the ability of CD8+ T-cells to secrete IFNγ in an antigen-specific manner suggest that T-cell mediated immunotherapies are perhaps better suited at preventing and treating relapsed and refractory AML. Here, IFNG is linked to acute myeloid leukemia.